Literature DB >> 32531502

Childhood cancer survivors: The integral role of the cardiologist and cardiovascular imaging.

Wendy J Bottinor1, Jonathan H Soslow2, Justin Godown2, Marcus F Stoddard3, Evan C Osmundson4, Carrie G Lenneman5, Debra L Friedman6, Scott C Borinstein6.   

Abstract

IMPORTANCE: With 80% of childhood cancer survivors (CCS) alive 30 years after diagnosis, preventable causes of death, such as cardiovascular disease resulting from initial cancer therapy, becomes an important metric. This leads to a more pronounced role for cardiologists in the care of CCS. OBSERVATIONS: While routine cardiovascular screening has been traditionally performed by the hematologist/oncologist or primary care provider, our understanding of cardiovascular disease in CCS has advanced. The measurement of left ventricular ejection fraction (LVEF) can now be complemented with additional assessments of strain, LV mass, right ventricular function, diastolic function, valve function, the pericardium, coronary perfusion, and biomarkers. Risk factor modification, prophylaxis, and timing of treatment are also critical. CONCLUSIONS AND RELEVANCE: Early cardiovascular screening and treatment in asymptomatic CCS can be nuanced and complex. As a result, there is a renewed opportunity for the cardiologist to play an integral role in the care of CCS. KEY POINTS: Question/Purpose: Review cardiovascular disease and the role of the cardiologist in the care of asymptomatic childhood cancer survivors (CCS).
FINDINGS: Cardiovascular care in CCS benefits from a multi-faceted approach that does not overly rely on LVEF. Meaning: Adequate screening and treatment of cardiovascular disease in asymptomatic CCS may often be optimized by the involvement of a cardiologist.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32531502     DOI: 10.1016/j.ahj.2020.05.008

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

1.  Thioredoxin Decreases Anthracycline Cardiotoxicity, But Sensitizes Cancer Cell Apoptosis.

Authors:  Kumuda C Das; Harish Muniyappa; Venkatesh Kundumani-Sridharan; Jaganathan Subramani
Journal:  Cardiovasc Toxicol       Date:  2020-09-03       Impact factor: 3.231

2.  Cardiac Surveillance for Early Detection of Late Subclinical Cardiac Dysfunction in Childhood Cancer Survivors After Anthracycline Therapy.

Authors:  Rosaria Sofia; Veronica Melita; Antonio De Vita; Antonio Ruggiero; Alberto Romano; Giorgio Attinà; Lisa Birritella; Priscilla Lamendola; Antonella Lombardo; Gaetano Antonio Lanza; Angelica Bibiana Delogu
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.